Anxiety

Anxiety during perimenopause and menopause arises from hormonal changes that disrupt neurotransmitter systems, stress-response pathways, and brain function. These hormonal shifts affect the body differently in each stage but share common biochemical mechanisms. Here’s how both phases influence anxiety:

1. Hormonal Fluctuations in Perimenopause
Estrogen Fluctuations:

During perimenopause, estrogen levels rise and fall unpredictably. This instability disrupts serotonin production and receptor sensitivity, leading to mood swings and heightened anxiety.

Estrogen also regulates dopamine, which affects motivation and emotional stability. Fluctuations can impair these pathways, contributing to feelings of restlessness or panic.

Progesterone Decline:

Progesterone levels begin to drop during perimenopause, reducing the production of allopregnanolone (ALLO), a metabolite that enhances GABA activity (the brain’s calming neurotransmitter). Lower ALLO levels result in reduced inhibition of overactive brain circuits, increasing susceptibility to anxiety.

2. Hormonal Deficiency in Menopause
Estrogen Deficiency:

In menopause, estrogen levels stabilize at much lower levels compared to perimenopause. This chronic deficiency reduces serotonin production and receptor density in the brain, leading to persistent anxiety or depression.

Estrogen’s neuroprotective effects on brain-derived neurotrophic factor (BDNF), which supports neuron health and resilience to stress, are diminished. This makes the brain less adaptable to stressors.

Progesterone Absence:

Progesterone production ceases entirely after menopause, eliminating ALLO synthesis. Without ALLO’s calming effects on GABA receptors, the brain becomes more prone to excitatory signals that trigger anxiety.

3. Cortisol Dysregulation
Both perimenopause and menopause affect the hypothalamic-pituitary-adrenal (HPA) axis:

Perimenopause:

Estrogen fluctuations destabilize cortisol regulation, leading to spikes in cortisol during stressful situations. High cortisol amplifies amygdala activity (fear center of the brain) and reduces hippocampal function (memory and emotional regulation), worsening anxiety.

Menopause:

Chronic low estrogen removes its inhibitory effect on corticotropin-releasing hormone (CRH), causing prolonged cortisol elevation. This contributes to a "fight-or-flight" state even in non-threatening situations.

4. Neurotransmitter Imbalances
Both stages disrupt key neurotransmitters involved in anxiety regulation:

Serotonin: Declining estrogen reduces serotonin synthesis and receptor sensitivity, impairing mood stabilization.

GABA: Progesterone withdrawal decreases GABA activity, leading to hyperactive neural circuits associated with fear and panic.

Dopamine: Estrogen influences dopamine release; its decline affects motivation and emotional regulation.

5. Thyroid Function
Hormonal changes during both perimenopause and menopause can impact thyroid function:

Hypothyroidism (low thyroid hormone) slows metabolism, leading to fatigue-related anxiety.

Hyperthyroidism (excess thyroid hormone) overstimulates adrenergic receptors, mimicking panic attacks with symptoms like rapid heartbeat and sweating.

6. Inflammation
Estrogen has anti-inflammatory properties that decline during both phases:

Pro-inflammatory cytokines like IL-6 and TNF-α increase during menopause, crossing the blood-brain barrier and activating microglia (immune cells in the brain). This inflammation can exacerbate anxiety symptoms.